S02.4 · Healthcare & Life Sciences
A $600-650B device market where AI-enabled imaging and surgical software are displacing hardware-only differentiation.
Medical devices and surgical technology is a $600-650B global market (2025E, Fortune Business Insights / Precedence Research) growing 5-7% forward, led by robotic surgery, cardiovascular devices and diabetes technology. The most consequential shift, though, is not in hardware at all. AI-enabled imaging and surgical-planning software is becoming the primary differentiator, and the hardware-only competitive position device makers have relied on for decades is eroding underneath them.
Historically the segment grew 5-6%; the forward projection is 5-7%. The US books roughly 40% of revenue, with the EU and Japan following; manufacturing sits in the US, Ireland, Costa Rica and Mexico, and lower-complexity device production keeps moving to China. The top 10 medtech strategics — Medtronic, J&J MedTech, Abbott, Stryker and Boston Scientific among them — hold roughly 35-40% combined share, with a deep long tail beneath them in surgical instruments and consumer-adjacent, direct-to-consumer devices.
Component and electronics suppliers and contract manufacturers sit upstream; hospitals, ambulatory surgical centers, physician offices and consumer/DTC channels sit downstream. Gross margins run 55-70%, protected by heavy regulatory gating — FDA 510(k)/PMA clearance and EU MDR compliance raise the bar on entry. The revenue model is the classic razor/razorblade structure: recurring consumables and service revenue riding on capital-equipment placements. And hospital reimbursement through DRG and CPT coding sets adoption speed regardless of clinical merit — a coding decision can matter more than the trial data.
The automation target is image interpretation and surgical-planning workflows, and the compressed cost is the radiologist and technician labor embedded in the device-adjacent care pathway. The structural consequence follows directly: software and algorithm differentiation is displacing hardware-only differentiation as the segment's primary value driver. A device maker whose position rested on manufacturing precision now competes on the quality of the AI layered on top of the device. Imaging AI is already underway; AI-guided surgical robotics at scale is a 2-5 year horizon.
The same dynamic creates a boundary problem. When an imaging device's value increasingly sits in its interpretation software rather than its hardware, the line between the device segment and the diagnostics segment blurs. Strategically, consumables and service bolt-ons remain the defensive play, protecting the installed base of placed capital equipment. Robotics and AI-imaging platforms are the expansionary bet — genuinely new procedure volume plus a higher-margin software layer, not defense of existing device share.